Patents by Inventor Noriko Tabayashi

Noriko Tabayashi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Malaria transmission blocking vaccine
    Patent number: 11427620
    Abstract: It is an object of the present invention to provide a transmission-blocking vaccine using an immunogenic protein which is specifically expressed in the oocyst stage of malaria parasites or a peptide fragment thereof, and an oral transmission-blocking vaccine capable of immunizing various animals involved in the malaria infectious cycle with such a vaccine. The present invention relates to a malaria transmission-blocking vaccine for oral administration containing an immunogenic protein derived from malaria parasite which is specifically expressed in the oocyst stage of malaria parasites or a peptide fragment thereof, and a method of blocking the transmission of malaria using the same.
    Type: Grant
    Filed: September 4, 2017
    Date of Patent: August 30, 2022
    Assignees: Hokusan Co., Ltd., National Institute of Advanced Industrial Science and Technology, School Juridical Person The Kitasato Institute
    Inventors: Noriko Tabayashi, Toru Gotanda, Hanae Sasaki, Noriko Itchoda, Uiko Kagaya, Takeshi Matsumura, Akira Ito, Hiromi Ikadai
  • MALARIA TRANSMISSION BLOCKING VACCINE
    Publication number: 20210292382
    Abstract: It is an object of the present invention to provide a transmission-blocking vaccine using an immunogenic protein which is specifically expressed in the oocyst stage of malaria parasites or a peptide fragment thereof, and an oral transmission-blocking vaccine capable of immunizing various animals involved in the malaria infectious cycle with such a vaccine. The present invention relates to a malaria transmission-blocking vaccine for oral administration containing an immunogenic protein derived from malaria parasite which is specifically expressed in the oocyst stage of malaria parasites or a peptide fragment thereof, and a method of blocking the transmission of malaria using the same.
    Type: Application
    Filed: September 4, 2017
    Publication date: September 23, 2021
    Applicants: Hokusan Co. Ltd., National Institute of Advanced Industrial Science and Technology, School Juridical Person The Kitasato Institute
    Inventors: Noriko Tabayashi, Toru Gotanda, Hanae Sasaki, Noriko Itchoda, Uiko Kagaya, Takeshi Matsumura, Akira Ito, Hiromi Ikadai
  • Therapeutic effect of oral interferon a administration on chronic intractable external otitis
    Patent number: 10799448
    Abstract: The object of the present invention is to provide a therapeutic agent illustrating an immediate and sustained effect on chronic intractable external otitis. The present invention provide a composition, pharmaceutical composition, food and feed for preventing and/or treating chronic intractable external otitis, each comprising interferon-? (IFN?) as an active ingredient. Orally administering the composition of the present invention can provide inhibition, alleviation, treatment and prevention for chronic intractable external otitis. According to the present invention, IFN? can give a sufficient effect even when administered in a very small amount.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: October 13, 2020
    Assignees: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, HOKUSAN CO. LTD
    Inventors: Akira Ito, Takeshi Matsumura, Toru Gotanda, Noriko Tabayashi, Noriko Itchoda, Takashi Aoki, Uiko Kagaya
  • THERAPEUTIC EFFECT OF ORAL INTERFERON A ADMINISTRATION ON CHRONIC INTRACTABLE EXTERNAL OTITIS
    Publication number: 20190029953
    Abstract: The object of the present invention is to provide a therapeutic agent illustrating an immediate and sustained effect on chronic intractable external otitis. The present invention provide a composition, pharmaceutical composition, food and feed for preventing and/or treating chronic intractable external otitis, each comprising interferon-? (IFN?) as an active ingredient. Orally administering the composition of the present invention can provide inhibition, alleviation, treatment and prevention for chronic intractable external otitis. According to the present invention, IFN? can give a sufficient effect even when administered in a very small amount.
    Type: Application
    Filed: January 12, 2016
    Publication date: January 31, 2019
    Applicants: National Institute of Advanced Industrial Science and Technology, Hokusan Co. Ltd
    Inventors: Akira Ito, Takeshi Matsumura, Toru Gotanda, Noriko Tabayashi, Noriko Itchoda, Takashi Aoki, Uiko Kagaya
  • Prevention of diarrhea
    Patent number: 9937271
    Abstract: The present invention provides an agent for controlling Escherichia coli diarrhea comprising a Shiga toxin as an active ingredient.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: April 10, 2018
    Assignees: IDEMITSU KOSAN CO., LTD., NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, HOKUSAN CO., LTD.
    Inventors: Kazutoshi Sawada, Takeshi Matsui, Eiji Takita, Takeshi Matsumura, Akira Ito, Noriko Tabayashi
  • PREVENTION OF ESCHERICHIA COLI DIARRHEA
    Publication number: 20170173179
    Abstract: The present invention provides an agent for controlling Escherichia coli diarrhea comprising a Shiga toxin as an active ingredient.
    Type: Application
    Filed: November 25, 2014
    Publication date: June 22, 2017
    Applicants: IDEMITSU KOSAN CO., LTD., NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, HOKUSAN CO. LTD
    Inventors: Kazutoshi SAWADA, Takeshi MATSUI, Eiji TAKITA, Takeshi MATSUMURA, Akira ITO, Noriko TABAYASHI
  • Adiponectin-containing eating behavior control agent for oral administration
    Patent number: 9181561
    Abstract: Disclosed is a technique that facilitates the oral ingestion of adiponectin in a large quantity and enables the expansion of the range of use applications of adiponectin. Specifically disclosed is an appetite control agent for oral administration, which comprises adiponectin as an active ingredient. Particularly, the appetite control agent comprises a transformant capable of expressing adiponectin. Also specifically disclosed is a food composition for controlling appetite, which comprises the appetite control agent.
    Type: Grant
    Filed: January 18, 2010
    Date of Patent: November 10, 2015
    Assignees: Hokusan Co., Ltd., National Institute of Advanced Industrial Science and Technology, National University Corporation Hokkaido University
    Inventors: Takeshi Matsumura, Rie Yasuno, Chihiro Sugimoto, Noriko Tabayashi, Uiko Kagaya, Hiroko Miyashiro
  • ADIPONECTIN-CONTAINING EATING BEHAVIOR CONTROL AGENT FOR ORAL ADMINISTRATION
    Publication number: 20120115776
    Abstract: Disclosed is a technique that facilitates the oral ingestion of adiponectin in a large quantity and enables the expansion of the range of use applications of adiponectin. Specifically disclosed is an appetite control agent for oral administration, which comprises adiponectin as an active ingredient. Particularly, the appetite control agent comprises a transformant capable of expressing adiponectin. Also specifically disclosed is a food composition for controlling appetite, which comprises the appetite control agent.
    Type: Application
    Filed: January 18, 2010
    Publication date: May 10, 2012
    Applicants: National Institute of Advanced Industrial Science, National University Corporation Hokkaido Universit, Hokusan Co., Ltd.
    Inventors: Takeshi Matsumura, Rie Yasuno, Chihiro Sugimoto, Noriko Tabayashi, Uiko Kagaya, Hiroko Miyashiro